Medical management of side effects related to CAR T cell therapy in hematologic malignancies.
about
Retroviral Vectors for Cancer Gene Therapy.Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma.The impact of antibiotic usage on the efficacy of chemoimmunotherapy is contingent on the source of tumor-reactive T cells.Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design.Genetically enhanced T lymphocytes and the intensive care unit.Nephrotoxicity of Cancer Immunotherapies: Past, Present and FutureThe biological basis and clinical symptoms of CAR-T therapy-associated toxicites
P2860
Q39094431-5F59B903-9C12-4ADE-A36B-A94FBAD2C325Q47589152-A7BEAAB4-60C7-46DE-8A1C-7BFE4A33C866Q49276632-74481A88-CB6C-4C85-8C41-A31DB376E260Q55317069-2AEA71D5-D48B-484D-82ED-EA46AA7E4541Q55380614-C3DD8248-D330-4B72-98EC-BA9F8941DA9FQ57172529-27B72A7D-23E7-4A5E-8BEE-AEDF108ACE4DQ58765358-7B210726-6A21-4609-A501-39421D852BD2
P2860
Medical management of side effects related to CAR T cell therapy in hematologic malignancies.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Medical management of side eff ...... y in hematologic malignancies.
@en
type
label
Medical management of side eff ...... y in hematologic malignancies.
@en
prefLabel
Medical management of side eff ...... y in hematologic malignancies.
@en
P2860
P1476
Medical management of side eff ...... y in hematologic malignancies.
@en
P2093
Manjusha Namuduri
Renier J Brentjens
P2860
P304
P356
10.1080/17474086.2016.1183479
P577
2016-05-03T00:00:00Z